Nature Reviews Clinical Oncology最新文献

Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-01-24 DOI: 10.1038/s41571-025-00987-2

Omar Nadeem, Irene M. Ghobrial

引用次数: 0

Adding brentuximab vedotin to lenalidomide and rituximab improves OS in R/R DLBCL 来那度胺和利妥昔单抗联合brentuximab vedotin可改善R/R DLBCL的OS

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-01-20 DOI: 10.1038/s41571-025-00988-1

David Killock

引用次数: 0

Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation? 早期和局部晚期 NSCLC 中的循环肿瘤 DNA：是否已准备好临床应用？

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-01-20 DOI: 10.1038/s41571-024-00985-w

Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, Vincenzo Sforza, Lorenza Landi, Emilio Bria, Angelo Delmonte, Federico Cappuzzo, Antonella De Luca

{"title":"Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?","authors":"Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, Vincenzo Sforza, Lorenza Landi, Emilio Bria, Angelo Delmonte, Federico Cappuzzo, Antonella De Luca","doi":"10.1038/s41571-024-00985-w","DOIUrl":"https://doi.org/10.1038/s41571-024-00985-w","url":null,"abstract":"Circulating tumour DNA (ctDNA) can be released by cancer cells into biological fluids through apoptosis, necrosis or active release. In patients with non-small-cell lung cancer (NSCLC), ctDNA levels correlate with clinical and pathological factors, including histology, tumour size and proliferative status. Currently, ctDNA analysis is recommended for molecular profiling in patients with advanced-stage NSCLC. In this Review, we summarize the increasing evidence suggesting that ctDNA has potential clinical applications in the management of patients with early stage and locally advanced NSCLC. In those with early stage NSCLC, detection of ctDNA before and/or after surgery is associated with a greater risk of disease recurrence. Longitudinal monitoring after surgery can further increase the prognostic value of ctDNA testing and enables detection of disease recurrence earlier than the assessment of clinical or radiological progression. In patients with locally advanced NSCLC, the detection of ctDNA after chemoradiotherapy is also associated with a greater risk of disease progression. Owing to the limited number of patients enrolled and the different technologies used for ctDNA testing in most of the clinical studies performed thus far, their results are not sufficient to currently support the routine clinical use of ctDNA monitoring in patients with early stage or locally advanced NSCLC. Therefore, we discuss the need for interventional studies to provide evidence for implementing ctDNA testing in this setting.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"24 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142990884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach 肿瘤浸润淋巴细胞在免疫治疗时代的生物学和临床意义：多维途径

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-01-16 DOI: 10.1038/s41571-024-00984-x

Miguel Lopez de Rodas, Maria Villalba-Esparza, Miguel F. Sanmamed, Lieping Chen, David L. Rimm, Kurt A. Schalper

{"title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","authors":"Miguel Lopez de Rodas, Maria Villalba-Esparza, Miguel F. Sanmamed, Lieping Chen, David L. Rimm, Kurt A. Schalper","doi":"10.1038/s41571-024-00984-x","DOIUrl":"https://doi.org/10.1038/s41571-024-00984-x","url":null,"abstract":"Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes across several solid tumour types. Prominent efforts have focused on understanding the anticancer mechanisms of these agents, identifying biomarkers of response and uncovering resistance mechanisms to develop new immunotherapeutic approaches. This research has underscored the crucial roles of the tumour microenvironment and, particularly, tumour-infiltrating lymphocytes (TILs) in immune-mediated tumour elimination. Numerous studies have evaluated the prognostic and predictive value of TILs and the mechanisms that govern T cell dysfunction, fuelled by technical developments in single-cell transcriptomics, proteomics, high-dimensional spatial platforms and advanced computational models. However, questions remain regarding the definition of TILs, optimal strategies to study them, specific roles of different TIL subpopulations and their clinical implications in different treatment contexts. Additionally, most studies have focused on the abundance of major TIL subpopulations but have not developed standardized quantification strategies or analysed other crucial aspects such as their functional profile, spatial distribution and/or arrangement, tumour antigen-reactivity, clonal diversity and heterogeneity. In this Review, we discuss a conceptual framework for the systematic study of TILs and summarize the evidence regarding their biological properties and biomarker potential for ICI therapy. We also highlight opportunities, challenges and strategies to support future developments in this field.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions 晚期鳞状细胞肺癌的免疫治疗：现状和悬而未决的问题

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-01-06 DOI: 10.1038/s41571-024-00979-8

Yibei Wang, Mohammed Safi, Fred R. Hirsch, Shun Lu, Solange Peters, Ramaswamy Govindan, Rafael Rosell, Keunchil Park, Jianjun J. Zhang

{"title":"Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions","authors":"Yibei Wang, Mohammed Safi, Fred R. Hirsch, Shun Lu, Solange Peters, Ramaswamy Govindan, Rafael Rosell, Keunchil Park, Jianjun J. Zhang","doi":"10.1038/s41571-024-00979-8","DOIUrl":"https://doi.org/10.1038/s41571-024-00979-8","url":null,"abstract":"Immune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-stage squamous non-small-cell lung cancer (LUSC), a histological subtype associated with inferior outcomes compared with lung adenocarcinoma. However, only a subset of patients derive durable clinical benefit. In the first-line setting, multiple ICI regimens are available, including anti-PD-(L)1 antibodies as monotherapy, in combination with chemotherapy, or with an anti-CTLA4 antibody with or without chemotherapy. Several important questions persist regarding the optimal regimen for individual patients, particularly how to identify patients who might benefit from adding chemotherapy and/or anti-CTLA4 antibodies to anti-PD-(L)1 antibodies. An urgent need exists for predictive biomarkers beyond PD-L1 to better guide precision oncology approaches. Deeper knowledge of the underlying molecular biology of LUSC and its implications for response to ICIs will be important in this regard. Integration of this knowledge into multi-omics methods coupled with artificial intelligence might enable the development of more robust biomarkers. Finally, several novel therapeutic strategies, including novel ICIs, bispecific antibodies and personalized cancer vaccines, are emerging. Addressing these unresolved questions through innovative clinical trials and translational research will be crucial to further improving the outcomes of patients with LUSC. In this Review, we provide a comprehensive overview of current immunotherapeutic approaches, unresolved challenges and emerging strategies for patients with LUSC.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"12 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142929402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment advances across the cervical cancer spectrum 宫颈癌的治疗取得了进展

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-01-03 DOI: 10.1038/s41571-024-00977-w

Alex A. Francoeur, Bradley J. Monk, Krishnansu S. Tewari

{"title":"Treatment advances across the cervical cancer spectrum","authors":"Alex A. Francoeur, Bradley J. Monk, Krishnansu S. Tewari","doi":"10.1038/s41571-024-00977-w","DOIUrl":"https://doi.org/10.1038/s41571-024-00977-w","url":null,"abstract":"Cervical cancer is preventable with screening and vaccination approaches; however, access to these preventative measures is limited both nationally and globally and thus many women will still develop cervical cancer. Novel treatments and practice-changing research have improved cervical cancer outcomes over the past few decades. In this Review, we discuss clinical trials that have refined or redefined the treatment of cervical cancers across the early stage, locally advanced, persistent, recurrent and/or metastatic disease settings. Advances for patients with early stage disease have been achieved through trials evaluating less extensive and fertility-preserving surgeries, different surgical approaches (open versus minimally invasive), and sentinel versus full pelvic lymph node dissection. We also discuss results from trials testing the use of neoadjuvant, induction and adjuvant chemotherapy as well as immune-checkpoint inhibitors in patients with locally advanced disease. Finally, we review the progress made with systemic chemotherapy and novel therapeutics, including anti-angiogenic agents, immune-checkpoint inhibitors and antibody–drug conjugates, in the setting of metastatic and/or recurrent cervical cancer. The advances highlighted in this manuscript have reduced morbidity and improved overall survival for patients with this challenging-to-treat disease, while also inspiring additional research and trials in the field.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"27 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142917102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Women with clinically node negative breast cancer can safely avoid axillary surgery 临床淋巴结阴性乳腺癌的妇女可以安全地避免腋窝手术

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-01-03 DOI: 10.1038/s41571-024-00982-z

Peter Sidaway

引用次数: 0

Imlunestrant shows efficacy both with and without abemaciclib 服用和不服用阿贝马西林均有疗效

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-01-02 DOI: 10.1038/s41571-024-00983-y

David Killock

{"title":"Imlunestrant shows efficacy both with and without abemaciclib","authors":"David Killock","doi":"10.1038/s41571-024-00983-y","DOIUrl":"https://doi.org/10.1038/s41571-024-00983-y","url":null,"abstract":"Various endocrine therapies and CDK4/6 inhibitors have improved the treatment of ER+HER2−breast cancer, although resistance remains common and often involves ESR1 (encoding ERα) mutations. Now, data from the phase III EMBER-3 trial demonstrate that the next-generation, brain-penetrant, oral selective ER degrader imlunestrant delays disease progression in previously treated patients with ESR1 mutations, and regardless of ESR1 status when combined with abemaciclib.In EMBER-3, patients with progression of ER+ HER2− breast cancer during or ≤1 year after completing (neo)adjuvant therapy with an aromatase inhibitor, or during first-line treatment for advanced-stage disease, were randomly assigned to receive imlunestrant (n = 331), standard endocrine therapy (exemestane or fulvestrant; n = 330), or imlunestrant–abemaciclib (n = 213). The majority of patients (59.8%) had also received a prior CDK4/6 inhibitor, most for advanced-stage disease. The primary end points were progression-free survival (PFS) with imlunestrant versus standard therapy among patients with ESR1 mutations and among all patients, and with imlunestrant–abemaciclib versus imlunestrant among all patients.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"5 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

cfDNA screening for fetal aneuploidy facilitates maternal cancer detection 胎儿非整倍体cfDNA筛查有助于发现母体癌症

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-01-02 DOI: 10.1038/s41571-024-00981-0

David Killock

引用次数: 0

Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL 在化疗基础上加用blinatumomab可降低标准风险儿科B-ALL的复发风险

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-12-17 DOI: 10.1038/s41571-024-00980-1

Peter Sidaway

引用次数: 0